EUCTR2014-003836-38-DK
Active, not recruiting
Phase 1
A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR Prior Treatment Failure Subjects with Chronic HCV GT1, 4 or 6 Infection - MK-5172/MK-8742 vs Sofosbuvir/PR in HCV GT1, 4 or 6 Infection
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.0 sites256 target enrollmentDecember 19, 2014
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Hepatitis C
- Sponsor
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
- Enrollment
- 256
- Status
- Active, not recruiting
- Last Updated
- 9 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •You are greater than or equal to 18 years of age
- •You have chronic HCV GT1
- •You have had a liver biopsy, Fibroscan or Fibrotest to check for cirrhosis or no cirrhosis
- •Have documented chronic HCV GT 1, 4 or 6 (with no evidence of non\-typeable or mixed genotype) infection:
- •\-Positive for anti\-HCV antibody, HCV RNA, or HCV GT 1, 4 or 6 at least 6 months before screening (HCV RNA and HCV genotype must be confirmed by screening lab results), or
- •\-Positive for anti\-HCV antibody or HCV RNA at the time of screening with a liver biopsy consistent with chronic HCV infection (or a liver biopsy performed before enrollment with evidence of CHC disease, such as the presence of fibrosis)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 230
Exclusion Criteria
- •You have signs of decompensated liver disease
- •You are coninfected with Hepatitis B
- •You have signs of hepatocellular carcinoma or history of malignancy
- •You are taking or plan to take any medication not allowed for this study
- •You have a history of, or signs of, chronic hepatitis not caused by hepatitis C virus
- •You have pre\-existing psychiatric condition
- •You have an exclusionary laboratory value
- •You intend to become pregnant or plan to impregnate during the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
MK-5172/MK-8742 vs Sofosbuvir/PR in HCV GT1, 4 or 6 InfectioHepatitis CMedDRA version: 17.1 Level: LLT Classification code 10019751 Term: Hepatitis C virus System Organ Class: 100000004848Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2014-003836-38-NOMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.257
Active, not recruiting
Not Applicable
Russian Registration Study of PPV23Vaccination against pneumococcal disease caused by the 23 serotypes included in the vaccineTherapeutic area: Body processes [G] - Immune system processes [G12]EUCTR2015-001656-29-Outside-EU/EEAMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.102
Active, not recruiting
Phase 1
MK-5172/MK-8742 vs Sofosbuvir/PR in HCV GT1, 4 or 6 InfectioEUCTR2014-003836-38-CZMerck Corporation, Inc.256
Active, not recruiting
Not Applicable
MK-5172/MK-8742 vs Sofosbuvir/PR in HCV GT1, 4 or 6 InfectioHepatitis CMedDRA version: 17.1Level: LLTClassification code 10019751Term: Hepatitis C virusSystem Organ Class: 100000004848Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2014-003836-38-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.256
Active, not recruiting
Phase 1
MK-5172/MK-8742 vs Sofosbuvir/PR in HCV GT1, 4 or 6 InfectioHepatitis CMedDRA version: 17.1Level: LLTClassification code 10019751Term: Hepatitis C virusSystem Organ Class: 100000004848Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2014-003836-38-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.256